Article
Emergent resistance-associated mutations at first- or second-line HIV-1 virologic failure with second-generation InSTIs in two- and three-drug regimens: the Virostar-1 study.
The Journal of antimicrobial chemotherapy - 3 Jan 2025
Marcelin Anne-Geneviève, Soulie Cathia, Wirden Marc, Barriere Guillaume, Durand François, Charpentier Charlotte, Descamps Diane, Calvez Vincent
Abstract excerpt
BACKGROUND: Second-generation integrase strand transfer inhibitors (InSTIs) have a high barrier to resistance and potent antiretroviral activity. They are recommended as first- or second-line (FL and SL) options in two- and three-drug regimens (2DR and 3DR) in international treatment guidelines. However, there are limited real-world data on emerging resistance at the time of virological failure (VF) with these...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.